FDA clears TransCorp Spine's SpinePort System

TransCorp Spine announced Thursday that it received FDA clearance for its SpinePort Spinal Access System, which provides direct access and visualisation when treating cervical spine pathologies through a transcorporeal microdecompression procedure. The system can also be used to collect autograft bone locally, which eliminates the need for a second incision during cervical fusion procedures.

CEO Christopher Welch commented that the SpinePort System "is the first of several products that TransCorp Spine is developing to provide... an alternative to traditional cervical fusion procedures." The device was initially launched in the US in 2011.

Did you like this article?